Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction

The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2 and ERK1 and ERK2 but t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Platelets
Main Authors: Unsworth, Amanda J., Bye, Alexander P., Kriek, Neline, Sage, Tanya, Osborne, Ashley A., Donaghy, Dillon, Gibbins, Jonathan M.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://ncbi.nlm.nih.gov/pubmed/30252580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/09537104.2018.1514107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados